No new safety signals were reported with the androgen receptor pathway inhibitor.
Danielle Ternyila
Advertisement
Articles by Danielle Ternyila
Advertisement
Latest Updated Articles
Subgroup data sustain enzalutamide PFS benefit in nmCRPCDecember 7th 2020
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves tebipenem pivoxil for complicated urinary tract infections
2
Behind the FDA approval of capivasertib for mHSPC, with Daniel J. George, MD
3
FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia
4
The ArteraAI Prostate Test: What It Is and How It Works
5